ClinicalTrials.gg

Program

Chimeric Antigen Receptor T-cells

Also written as “Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103”, “CAR T cells” and “CAR-T cells”.

Its studies are mostly in Glioma · Lymphoma, Non-Hodgkin · Colorectal Neoplasms · Leukemia, Myeloid, Acute · Carcinoma, Hepatocellular, led by 7 companies.

Furthest: phase 3, since Jun 15, 20248 company-led studies, 4 open or runningNext primary completion: May 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tcelltech21 open or runningphase 1since Jun 15, 2024Jun 15, 2024none ahead
AGC Biologics10 open or runningphase 2since Aug 5, 2019Aug 5, 2019none ahead
Chongqing Precision Biotech11 open or runningphase 1since Jun 12, 2022Jun 12, 2022none ahead
Imunopharm Technology10 open or runningphase 1since Jan 27, 2021Jan 27, 2021none ahead
Shanghai Cell Therapy Group11 open or runningphase 1since Oct 11, 2021Oct 11, 2021none ahead
Shanghai GeneChem10 open or runningphase 2since Nov 6, 2016Nov 6, 2016none ahead
Suzhou Immunofoco Biotechnology11 open or runningphase 3since Jul 17, 2025Jul 17, 2025May 31, 2027phase 3 · NCT07103668

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 6, 2016First study: phase 2 study in Carcinoma, HepatocellularNew to Shanghai GeneChemShanghai GeneChem · NCT02959151 · 20 enrolled · China
  2. Aug 5, 2019AGC Biologics’ first study: phase 2 study in Leukemia, Myeloid, AcuteNew to AGC BiologicsAGC Biologics · NCT04097301 · 8 enrolled · Czechia, Italy
  3. Jan 27, 2021Imunopharm Technology’s first study: phase 1 study in AMLNew to Imunopharm TechnologyImunopharm Technology · NCT04766840 · 9 enrolled · China
  4. Oct 11, 2021Shanghai Cell Therapy Group’s first study: phase 1 study in Colorectal NeoplasmsNew to Shanghai Cell Therapy GroupShanghai Cell Therapy Group · NCT05089266 · 30 planned · China
  5. Jun 12, 2022Chongqing Precision Biotech’s first study: phase 1 study in Lymphoma, Non-HodgkinNew to Chongqing Precision BiotechChongqing Precision Biotech · NCT05420493 · 54 planned · China
  6. Jun 15, 2024Tcelltech’s first study: phase 1 study in GliomaNew to TcelltechTcelltech · NCT06482905 · 52 planned · United States, China
  7. Jul 17, 2025Suzhou Immunofoco Biotechnology’s first study: phase 3 study in Gastric AdenocarcinomaNew to Suzhou Immunofoco BiotechnologySuzhou Immunofoco Biotechnology · NCT07103668 · 150 planned · China
  8. Nov 13, 2025Phase 1 study in Solid TumorsTcelltech · NCT07231081 · 85 enrolled · China

Ahead

  1. May 31, 2027Primary completion: phase 3 study in Gastric AdenocarcinomaSuzhou Immunofoco Biotechnology · NCT07103668

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07231081Solid Tumors · China1SuspendedTcelltechDec 20, 202785
NCT07103668Gastric Adenocarcinoma · China3RecruitingSuzhou Immunofoco BiotechnologyMay 31, 2027150
NCT06482905Glioma · United States, China1RecruitingTcelltechSep 202652
NCT05420493Lymphoma, Non-Hodgkin · China1RecruitingChongqing Precision BiotechSep 30, 202454
NCT05089266Colorectal Neoplasms · China1RecruitingShanghai Cell Therapy GroupJul 30, 202430
NCT04766840AML · China1UNKNOWNImunopharm TechnologyJun 1, 20239
NCT04097301Leukemia, Myeloid, Acute · Czechia, Italy2TerminatedAGC BiologicsJun 18, 20218
NCT02959151Carcinoma, Hepatocellular · China2UNKNOWNShanghai GeneChemJan 201820

How it is read

Names in the registry

  • “Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103”, 2 entries
  • “CAR T cells”, 2 entries
  • “CAR-T cells”, 2 entries
  • “MLM-CAR44.1 T-cells at day 0 Single intravenous infusion”, 1 entry
  • “CAR-T cell”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Chimeric Antigen Receptor T-cells (Tcelltech): development program | ClinicalTrials.gg